Daclatasvir (dihydrochloride)

Daclatasvir (dihydrochloride)

• CAS Number: 1009119-65-6
• UNSPSC Description: Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir dihydrochloride is also an organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 μM and 3.27 μM, respectively[1][2][3].
• Target Antigen: HCV
• Type: Reference compound
• Related Pathways: Anti-infection
• Applications: COVID-19-anti-virus
• Field of Research: Infection
• Assay Protocol: https://www.medchemexpress.com/Daclatasvir-dihydrochloride.html
• Purity: 99.68
• Solubility: DMSO : ≥ 56 mg/mL|H2O : 50 mg/mL (ultrasonic)
• Smiles: O=C(N1CCC[C@H]1C2=NC=C(C3=CC=C(C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C([C@H](C(C)C)NC(OC)=O)=O)C=C3)N2)[C@H](C(C)C)NC(OC)=O.[H]Cl.[H]Cl
• Molecular Weight: 811.80
• References & Citations: [1]Min Gao, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010 May 6;465(7294):96-100.|[2]David B Ascher, et al. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep. 2014 Apr 23;4:4765.|[3]Tomomi Furihata, et al. Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. Antimicrob Agents Chemother. 2014 Aug;58(8):4555-64.|[4]Seung-Hoon Lee, et al. HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice. Sci Rep. 2018 Aug 20;8(1):12469.EMBO Mol Med. 2024 Mar 10.|Ann Hepatol. Nov-Dec 2019;18(6):816-824.|Antimicrob Agents Chemother. 2013 Mar;57(3):1180-91.|Antimicrob Agents Chemother. 2014 Aug;58(8):4555-64.|Antimicrob Agents Chemother. 2014 Jun;58(6):3327-34. |Antimicrob Agents Chemother. 2015 May;59(5):2496-507. |Antivir Res. 2019 Nov;171:104612.|Antiviral Res. 2017 Dec;148:5-14. |Antiviral Res. 2017 Oct;146:191-200. |Antiviral Res. 2020 May;177:104734.|Biomed Pharmacother. 2019 May 16;116:108976.|Biomed Pharmacother. 2024 Sep 2:179:117325.|bioRxiv. 2020 May.|Cell Rep. 2021 Nov 23;37(8):110049.|College of Medicine/School of Medicine. Seoul National University. 2016 Aug.|Department of Analytical Chemistry. Charles University. 2019 Jun.|Drug Metab Dispos. 2019 Jul;47(7):768-778. |EMBO Rep. 2016 Jul;17(7):1013-28.|Eur J Med Chem. 2018 Jan 1;143:1053-1065.|Eur J Pharmacol. 2019 Jun 15;853:111-120.|Eur J Pharmacol. 2020 Sep 15;883:173323.|Faculty of Pharmacy in Hradec Králové. Department of Pharmacology and Toxicology. Charles University 2019 Apr.|Front Pharmacol. 2016 Dec 21;7:490. |Front Pharmacol. 2018 Dec 19;9:1438.|Hepatol Commun. 2017 Jul 13;1(6):550-563.|Hepatology. 2019 May;69(5):1861-1872. |Int J Antimicrob Agents. 2015 Oct;46(4):381-8. |Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):867-876. |J Gastroenterol. 2019 May;54(5):449-458. |J Hum Genet. 2020 Jan;65(2):143-153.|J Med Chem. 2020 Jun 11;63(11):5972-5989.|J Med Virol. 2023 Dec;95(12):e29290.|J Virol. 2014 May;88(10):5578-94. |Oncotarget. 2017 Dec 21;9(5):5627-5640.|Open Virol J. 2014 Mar 7;8:1-8.|Pharmaceuticals. 2022 Feb 18;15(2):242.|PLoS One. 2015 Aug 11;10(8):e0134707. |PLoS One. 2016 Apr 22;11(4):e0152036. |PLoS One. 2016 Jul 21;11(7):e0159511.|PLoS Pathog. 2017 May 11;13(5):e1006374. |PLoS Pathog. 2018 Sep 18;14(9):e1007284. |Sci Rep. 2018 Jun 6;8(1):8676. |Transpl Infect Dis. 2018 Feb;20(1).|University of Glasgow. 2024 Mar.|Virus Res. 2017 May 2;235:37-48.|Viruses. 2018 Aug 28;10(9). pii: E462.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: Launched